What Is Cagrilintide? Amylin Analogue Research Guide
Cagrilintide is a long-acting, lipidated amylin analogue that activates amylin and calcitonin receptors. How it was designed, what published trials reported, and how to verify it in the lab.
Cagrilintide is a long-acting, lipidated analogue of the pancreatic hormone amylin. It activates amylin receptors and the calcitonin receptor, and was engineered to avoid the fibril formation that makes native human amylin difficult to work with. It has been studied in phase 1–3 trials, alone and combined with semaglutide (CagriSema).
What is cagrilintide?
Cagrilintide is a synthetic, fatty-acid-modified analogue of amylin developed by Novo Nordisk as a long-acting research and clinical candidate. Kruse and colleagues described it in 2021 as a “stable, lipidated long-acting amylin analogue,” selected after a structure–activity program aimed at overcoming two limits of earlier amylin mimetics: poor physical stability and a short half-life (Kruse et al., 2021).
In the scientific literature it is often grouped with “dual amylin and calcitonin receptor agonists,” because it is non-selective across the receptor family that amylin and calcitonin share. Soraci Labs supplies it as Cagrilintide 10mg for laboratory research.
What is amylin, and why is it hard to work with?
Amylin (islet amyloid polypeptide, IAPP) is a 37-residue peptide hormone co-secreted with insulin by pancreatic β-cells. In physiology research it is studied for its roles in gastric emptying, glucagon secretion after meals, and satiety signalling through the brainstem area postrema (Hay et al., 2015).
Native human amylin is a difficult molecule. It readily self-assembles into amyloid fibrils, and the aggregates are insoluble and cytotoxic in cell models. The first approved analogue, pramlintide, addressed this by borrowing proline residues from the non-aggregating rat sequence, but its short half-life required multiple daily injections. Cagrilintide’s design targeted both problems at once: substitutions that suppress fibrillation plus a lipid side chain that extends circulation time (Kruse et al., 2021).
How does cagrilintide work at the receptor level?
Cagrilintide activates amylin receptors and the calcitonin receptor. Amylin receptors are not single proteins: each is the calcitonin receptor (CTR), a class B GPCR, paired with one of three receptor activity-modifying proteins (RAMP1–3). The pairings give AMY1, AMY2 and AMY3 receptors, each with distinct ligand preferences (Hay et al., 2015).
Because cagrilintide acts across AMY receptors and CTR, it is pharmacologically distinct from incretin mimetics such as semaglutide or tirzepatide, which target the GLP-1 and GIP receptors. That difference is the scientific rationale for studying the two classes together. For background on the incretin side, see our guide to single, dual and triple GLP-1/GIP/glucagon agonists.
What has published research reported on cagrilintide?
Cagrilintide has progressed from phase 1 to phase 3 trials, with body-weight change as the primary endpoint in the main studies and gastrointestinal events as the most frequently reported adverse events. The table summarizes the key peer-reviewed reports.
| Study | Design | Participants / duration | Reported findings |
|---|---|---|---|
| Enebo et al., Lancet 2021 | Phase 1b, randomized, placebo-controlled; cagrilintide co-administered with semaglutide | Adults with overweight or obesity; multiple ascending dose levels | Characterized safety, tolerability and pharmacokinetics of the combination; supported further development |
| Lau et al., Lancet 2021 | Phase 2, double-blind, placebo- and active-controlled (liraglutide), five dose levels | 706 adults without diabetes; 26 weeks | Mean body-weight change of −6.0% to −10.8% across doses vs −3.0% with placebo; nausea, constipation, diarrhoea and injection-site reactions were most common |
| Garvey et al., NEJM 2025 (REDEFINE 1) | Phase 3a, double-blind; cagrilintide + semaglutide vs each alone vs placebo | 3,417 adults without diabetes; 68 weeks | Mean body-weight change of −20.4% with the combination vs −3.0% with placebo; GI events 79.6% vs 39.9% |
| Davies et al., NEJM 2025 (REDEFINE 2) | Phase 3a, double-blind, placebo-controlled | 1,206 adults with type 2 diabetes; 68 weeks | Mean body-weight change of −13.7% vs −3.4% with placebo; GI events 72.5% vs 34.4% |
These are summaries of published clinical data, not claims about any research-grade product. Full methods, populations and statistical analyses are in the papers listed under References.
Cagrilintide vs pramlintide vs semaglutide: what is the difference?
The three compounds differ in their parent hormone, receptor targets and the strategy used to extend their activity.
| Property | Cagrilintide | Pramlintide | Semaglutide |
|---|---|---|---|
| Parent hormone | Amylin | Amylin | GLP-1 |
| Main receptor targets | AMY1–3 receptors and calcitonin receptor | Amylin receptors | GLP-1 receptor |
| Anti-aggregation strategy | Sequence substitutions selected to suppress fibrillation | Proline substitutions from rat amylin | Not applicable (GLP-1 is not amyloidogenic in the same way) |
| Half-life extension | Fatty-acid (lipid) side chain | None; short-acting | Fatty-acid side chain promoting albumin binding |
| Dosing interval studied | Once weekly | Multiple daily | Once weekly |
| Status | Investigational (phase 3 reported 2025) | FDA-approved 2005 | Approved |
How should researchers handle and verify cagrilintide in the lab?
Treat cagrilintide like any high-value lipidated peptide: verify identity and purity on arrival, store it dry and cold, and minimize handling that encourages aggregation.
- Check the COA against the lot. The lot number on the vial should match the certificate. Our guide to reading a peptide COA explains each field; batch certificates are on the COA page.
- Confirm identity by mass spectrometry. The observed mass should match the theoretical mass of the full lipidated molecule, not just the peptide backbone. See how peptide molecular weight is calculated.
- Review HPLC purity. Look at the chromatogram, not only the percentage. Lipidated peptides elute late on reversed-phase columns, and closely eluting shoulders can indicate related impurities.
- Store lyophilized material at −20 °C, sealed, desiccated and protected from light. Details are in our peptide storage and stability guide.
- Plan solubilization before opening the vial. Amphipathic, acylated peptides can behave differently from short hydrophilic ones; our peptide solubility guide covers solvent choice for in vitro work.
- Aliquot solutions and avoid repeated freeze–thaw cycles, which promote aggregation and adsorption losses.
Frequently asked questions
References
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183–11194. doi:10.1021/acs.jmedchem.1c00565. PMID 34288673. PubMed
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564–600. PMID 26071095. PubMed
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736–1748. PMID 33894838. PubMed
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160–2172. doi:10.1016/S0140-6736(21)01751-7. PMID 34798060. PubMed
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635–647. doi:10.1056/NEJMoa2502081. PMID 40544433. PubMed
- Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025;393(7):648–659. doi:10.1056/NEJMoa2502082. PMID 40544432. PubMed
All Soraci Labs products are sold for laboratory, analytical and research purposes only. They are not intended for human consumption, medical use, diagnostic use, or the treatment of any disease or condition.
